Keratinising squamous cell carcinoma of nasopharynx – Diagnostics – Overview of Information and Clinical Research

Understanding how keratinising squamous cell carcinoma of the nasopharynx is diagnosed can help patients and their families prepare for what lies ahead. This rare form of cancer requires specific tests and procedures to confirm its presence and determine the best path forward for care.

Who Should Undergo Diagnostics

If you notice certain symptoms that last longer than two weeks or keep returning, it’s important to speak with a healthcare provider about diagnostic testing for nasopharyngeal cancer. The most common sign that prompts people to seek medical attention is a painless lump on the back of the neck, which may appear when cancer spreads to the lymph nodes and causes them to swell. This lump usually doesn’t hurt, which is why some people might ignore it at first, but it deserves medical evaluation.^[1]

Other symptoms that should lead you to consider diagnostic testing include ongoing problems with your ears, such as hearing loss that affects only one ear, a feeling of fullness in the ears, or ear infections that won’t go away even with treatment. Unlike children, adults don’t commonly get ear infections, so when an adult develops one without having a cold or upper respiratory infection, doctors should examine the nasopharynx carefully.^[6]

Additional warning signs include persistent headaches, especially those caused by problems with certain nerves in your head, as well as facial numbness or pain. Some people experience ringing in the ears, called tinnitus, or notice a stuffy nose that affects only one side. Nosebleeds, difficulty opening your mouth, trouble breathing or speaking, and blurred or double vision are also symptoms that warrant medical investigation.^[1]

Because many of these symptoms can be caused by conditions that are not cancer, having one or more of them doesn’t automatically mean you have nasopharyngeal cancer. However, the persistence or recurrence of these symptoms is what makes diagnostic testing necessary. Healthcare providers need to rule out cancer or catch it early if it is present.^[12]

⚠️ Important

People who notice a lump in their neck that doesn’t go away should not delay seeking medical care. While the lump is often painless and may seem harmless, it can be the first visible sign that cancer has spread to the lymph nodes. Early diagnosis significantly affects treatment options and outcomes.

Classic Diagnostic Methods

When a healthcare provider suspects nasopharyngeal cancer, the diagnostic process typically begins with a thorough physical examination. During this exam, the doctor will look inside your nose and throat, checking for any unusual signs. They will also feel your neck carefully to detect any swelling in the lymph nodes. The doctor will ask about your symptoms and your health habits, including whether you smoke or drink alcohol.^[13]

One of the most important diagnostic tools is a procedure called nasal endoscopy. This test allows the healthcare provider to see directly inside your nasopharynx, which is difficult to examine otherwise because it sits behind your nose and above the back of your throat. During a nasal endoscopy, the doctor uses a thin, flexible tube with a tiny camera on the end, called an endoscope. This tube can be gently passed through your nose or through the opening at the back of your throat that leads up into the nasopharynx.^[13]

Before the endoscopy begins, your doctor may use a local anesthetic spray to numb your nose and throat, making the procedure more comfortable. After the procedure, you’ll need to wait about an hour before eating or drinking anything, or until the numbness wears off completely. The endoscope gives the doctor a clear view of your nasopharynx and allows them to look for any masses or abnormal tissue.^[11]

If the doctor sees something suspicious during the endoscopy, the next step is to take a biopsy. A biopsy involves removing a small sample of tissue from the suspicious area so it can be examined under a microscope in a laboratory. For nasopharyngeal cancer, the tissue sample can often be taken during the same endoscopy procedure using special tools that pass through the endoscope. A specialist called a pathologist will then study the tissue sample to determine whether cancer cells are present and what type of cells are involved.^[13]

In some cases, if there is swelling in the lymph nodes in your neck, the doctor might use a needle to draw out some cells from these lymph nodes for testing. This is another way to obtain tissue for diagnosis. When patients present with swollen lymph nodes in the neck but no other obvious signs, finding material from the Epstein-Barr virus in the tissue using a technique called polymerase chain reaction (PCR) provides strong evidence that the cancer originated in the nasopharynx. This finding tells doctors they need to examine the nasopharynx area very carefully.^[6]

Once a diagnosis is confirmed through biopsy, additional tests are performed to determine the extent of the cancer, also known as the stage. These tests help doctors understand whether the cancer has spread beyond the nasopharynx to other parts of the body. Imaging tests play a crucial role in this staging process.^[13]

Several types of imaging tests may be used. A CT scan, also called a computed tomography scan, uses special X-ray equipment to take detailed pictures from different angles of areas inside your mouth, throat, and neck. A computer processes these images to create cross-sectional views of your body. Sometimes a dye is injected into your vein or given as a pill to swallow, which helps highlight organs and tissues more clearly on the X-ray images.^[6]

An MRI scan, which stands for magnetic resonance imaging, uses magnets, radio waves, and a computer to create very detailed pictures of the inside of your nasopharynx and neck. This test is particularly good at showing soft tissues and can help doctors see exactly how large the tumor is and whether it has grown into nearby structures.^[6]

A PET scan, or positron emission tomography scan, is another imaging test that may be ordered. This scan can show areas of the body where cells are more active than normal, which can indicate the presence of cancer. Sometimes PET scans are combined with CT scans to give doctors even more detailed information about where cancer might have spread.^[13]

In addition to these imaging tests, doctors may order blood tests. While blood tests alone cannot diagnose nasopharyngeal cancer, they can provide important information about your overall health and help detect whether the cancer has affected other organs. Blood tests can also measure levels of antibodies to the Epstein-Barr virus, which is strongly linked to certain types of nasopharyngeal cancer.^[6]

For keratinising squamous cell carcinoma specifically, which is also known as World Health Organization (WHO) type 1 nasopharyngeal cancer, the pathologist will look for cancer cells that are covered with keratin, a protein found in your hair and nails. This characteristic helps distinguish this type from other forms of nasopharyngeal cancer. The presence of keratin makes the outermost layer of the tumor harder. This type of nasopharyngeal cancer is more commonly found in older adults and is typically associated with risk factors like heavy smoking and alcohol consumption, rather than Epstein-Barr virus infection.^[1]^[12]

Diagnostics for Clinical Trial Qualification

When patients are being considered for participation in clinical trials, additional or more specific diagnostic tests may be required beyond those used for standard diagnosis and staging. Clinical trials often have strict inclusion and exclusion criteria that determine who can participate, and these criteria are designed to ensure the safety of participants and the accuracy of the research results.

One important diagnostic tool used in clinical trials for nasopharyngeal cancer is the measurement of circulating cancer-derived Epstein-Barr virus DNA in the blood. This test detects genetic material from the Epstein-Barr virus that is released into the bloodstream by cancer cells. For many clinical trials involving nasopharyngeal cancer, particularly those testing new treatments for non-keratinising types, measuring EBV DNA levels is a standard requirement. This measurement helps researchers assess how well a treatment is working and can serve as a marker for monitoring disease status throughout the trial.^[6]

However, it’s important to note that keratinising squamous cell carcinoma (WHO type 1) is not typically associated with Epstein-Barr virus infection. This means that for patients with this specific type of nasopharyngeal cancer, EBV DNA testing may not be relevant for clinical trial enrollment unless the trial specifically includes both EBV-positive and EBV-negative cases.^[10]

Clinical trials may also require more detailed imaging than what’s done for routine diagnosis. For example, some trials specify that patients must have measurable disease according to specific criteria, which means tumors must be of a certain size and clearly visible on imaging scans. This requirement allows researchers to accurately measure whether the tumor shrinks in response to treatment.^[6]

Additional blood tests may be required to ensure that patients entering a clinical trial have adequate organ function. These tests check the function of your kidneys, liver, and bone marrow to make sure your body can safely handle the experimental treatment being studied. Tests might include checking your blood cell counts, kidney function tests, and liver function tests.

Some clinical trials also require genetic testing of the tumor tissue to look for specific mutations or biomarkers. These molecular tests examine the DNA of cancer cells to identify particular genetic changes that might make the tumor more or less likely to respond to the treatment being studied in the trial.

The stage of cancer is always an important criterion for clinical trial qualification. Trials may be designed specifically for early-stage disease, advanced disease, or cancer that has come back after previous treatment. Accurate staging using the methods described earlier is essential to determine whether a patient meets the trial’s requirements.

For patients with keratinising squamous cell carcinoma who are interested in clinical trials, their doctors will review all diagnostic test results to determine which trials might be appropriate. Because this type represents less than 20 percent of nasopharyngeal cancer cases in the United States and has different characteristics from the more common non-keratinising types, some clinical trials may specifically include or exclude it based on the study design.^[10]

⚠️ Important

If you’re considering participating in a clinical trial, be prepared for additional diagnostic procedures beyond what you’ve already undergone. These extra tests are necessary to ensure the trial is safe for you and that researchers can accurately measure how well the treatment works. Your healthcare team will explain exactly which tests are needed and why.

Prognosis and Survival Rate

Prognosis

The prognosis for patients with nasopharyngeal cancer, including keratinising squamous cell carcinoma, depends on several important factors that doctors consider when estimating how the disease might progress and respond to treatment. The stage of cancer at diagnosis is the most significant factor affecting prognosis. Patients whose cancer is detected at an earlier stage, when the tumor is smaller and hasn’t spread beyond the nasopharynx, generally have better outcomes than those diagnosed at later stages when cancer has reached lymph nodes or distant organs. Unfortunately, most nasopharyngeal cancers are found at later stages, which affects overall prognosis.^[20]

The size of the tumor itself matters significantly. Smaller tumors, particularly those less than 2 centimeters in size, are associated with better prognoses compared to larger tumors. Whether the cancer has spread to lymph nodes in the neck is another crucial factor. When cancer reaches the lymph nodes, the prognosis becomes less favorable. Additionally, if the cancer has spread to lymph nodes in the lower areas of the neck, this suggests a higher likelihood that cancer may have also reached distant organs, further worsening the prognosis.^[20]

For keratinising squamous cell carcinoma specifically, research has shown that the presence of keratin in the cancer cells may influence how the disease behaves and responds to treatment. Patients with keratinising types have been found to have different patterns of disease progression compared to non-keratinising types. Studies have shown that patients with keratinising cancers tend to have a higher incidence of locally advanced tumors at diagnosis, but they may have a lower incidence of lymph node involvement compared to those with non-keratinising types.^[14]

The patient’s age plays a role in prognosis as well. People under 60 years old tend to have better outcomes than those over 60. This may be because younger patients generally have fewer other health problems and can better tolerate aggressive treatments. Speaking of other health conditions, patients who have additional medical issues such as heart disease, lung disease, or diabetes typically face a more challenging prognosis. These conditions, called comorbidities, can limit treatment options and affect overall health during cancer treatment.^[20]

After treatment is completed, the results of follow-up tests provide important prognostic information. For patients whose cancer was associated with Epstein-Barr virus (though this is less common with keratinising types), a high level of EBV antibodies in the blood after treatment indicates a less favorable prognosis and may suggest that cancer remains in the body or is likely to return. For all patients, the margin status after surgery matters significantly. If the surgeon can remove the tumor with clear margins—meaning no cancer cells are found at the edges of the removed tissue—the prognosis is much better than if cancer cells remain at the margins.^[20]

Survival rate

Specific survival rate statistics for keratinising squamous cell carcinoma of the nasopharynx as a distinct subtype are limited in the available medical literature. The type of nasopharyngeal cancer does influence survival, though stage remains the most powerful predictor. Generally speaking, non-keratinising squamous cell carcinoma has been associated with better survival outcomes than keratinising types in some studies, though this can vary based on other factors such as stage at diagnosis and treatment received.^[20]

Research has indicated that patients with keratinising squamous cell carcinoma may respond differently to treatment compared to those with non-keratinising types. The keratinising type is typically found in older adults and is more commonly associated with smoking and alcohol use rather than Epstein-Barr virus infection. These different underlying causes and characteristics may affect both how the disease progresses and how well it responds to radiation and chemotherapy.^[14]

Overall, nasopharyngeal cancer survival rates have improved significantly with modern treatment approaches that combine radiation therapy and chemotherapy. The lower the stage at diagnosis, the better the survival rate. Patients diagnosed with stage I disease have significantly better survival prospects than those diagnosed with stage IV disease. Regular follow-up care after treatment is essential for monitoring any signs that cancer might return, as early detection of recurrence allows for prompt intervention and better outcomes.

#1 Clinical Trials Search in Europe